Our panel of breast cancer PDX with different HER2 expression score and amplification pattern was used to study the effects of two drugs targeting HER2 with different mechanisms, the humanized monoclonal antibody trastuzumab and the small irreversible pan-HER tyrosine kinase inhibitor neratinib. Here, ERBB2 is linked to breast carcinoma.